News Snapshot:
BEIJING, Sept. 8 (Xinhua) -- China can currently realize an annual production of 300 million doses of a recombinant COVID-19 vaccine and will further expand its capacity, according to Chen Wei, head of the vaccine research team. A genetically engineered vaccine, the recombinant vaccine developed by the Institute of Military Medicine under the Academy of Military Sciences uses a modified defective adenovirus as the vector. The current data show a very low mutation probability of the gene that the team selected from the virus to make the vaccine. So far, the recombinant vaccine can completely cover all the mutations of...
